



Invitation

20 Extraordinary 26 General Meeting

of PolyPeptide Group AG

26 October 2026
18.00 (CET)

doors open at 17.30 (CET)

Dialoghotel Eckstein, Langgasse 9
6340 Baar, Switzerland

Invitation to Extraordinary General Meeting of Shareholders

Dear Shareholders,

On behalf of the Board of Directors, we are pleased to invite you to the extraordinary General Meeting of PolyPeptide Group AG, which will be held on 26 October 2026, 18.00 (CET), at Dialoghotel Eckstein, Langgasse 9, 6340 Baar, Switzerland (the "**EGM**").

The EGM has the following background:

On 17 July 2026, Samsung Biologics Co., Ltd. ("**Samsung Biologics**"), and PolyPeptide Group AG ("**PolyPeptide**" or the "**Company**") entered into a transaction agreement (the "**Transaction Agreement**"), pursuant to which Samsung Biologics agreed to make an all-cash public tender offer (the "**Offer**") to acquire all publicly held registered shares of PolyPeptide for CHF 44.31 per share, *minus* the gross amount of any dilutive effects in respect of the PolyPeptide shares prior to the consummation of the Offer (the "**Settlement**"), if any, as set out in the Offer Prospectus (as defined below). On the same day, Samsung Biologics entered into a tender undertaking (the "**Tender Undertaking**") with PolyPeptide's largest individual shareholder, Draupnir Holding B.V. ("**Draupnir**"), owning a stake of approximately 55.47% of the Company's issued share capital, pursuant to which Draupnir committed, *inter alia*, subject to the terms and conditions of the Tender Undertaking, to tender all its shares into the Offer.

Samsung Biologics published the pre-announcement of the Offer on 20 July 2026 (the "**Pre-Announcement**"). On 31 August 2026, Samsung Peptide AG, a wholly owned subsidiary of Samsung Biologics, published the offer prospectus for the Offer (the "**Offer Prospectus**"). The Board of Directors of PolyPeptide has, in accordance with its organizational regulations based on two resolutions (the first resolution passed by all members of the Board of Directors and the second resolution without Mr. Erik Schropp due to a potential conflict of interest), unanimously recommended that PolyPeptide's shareholders accept the Offer (see the report of the Board of Directors dated 28 August 2026).

The Offer is subject to the following Offer conditions, among others:

- that all members of the Board of Directors shall have resigned from their functions on the Board of Directors subject to and with effect from the Settlement and an extraordinary general meeting of shareholders shall have elected the persons nominated by Samsung Biologics as members of the Board of Directors (and one person as Chair and certain persons as members of the Remuneration and Nomination Committee, in each case as nominated by Samsung Biologics) subject to and with effect from the Settlement, or a sufficient number of members of the Board of Directors shall have resigned from their functions on the Board of Directors and/or entered into a mandate agreement with Samsung Biologics, in each case subject to and with effect from the Settlement, so that

Samsung Biologics will control the Board of Directors effective as of the Settlement (see Section B.7.1(g) of the Offer Prospectus); and

- that an extraordinary general meeting of shareholders shall have resolved, subject to all other Offer conditions having been satisfied or waived, to remove from the Articles of Association of the Company (i) the transfer restrictions (*Vinkulierung*) pursuant to Article 5 para. 3 of the Company's Articles of Association, and (ii) the voting limitations (*Stimmrechtsbeschränkungen*) pursuant to Article 11 para. 3 of the Company's Articles of Association, and these amendments of the Company's Articles of Association shall have been registered in the Commercial Register of the Canton of Zug (see Section B.7.1(e) of the Offer Prospectus).

Accordingly, pursuant to the Transaction Agreement, all members of the Board of Directors re-elected at the ordinary General Meeting of 8 April 2026, have tendered their resignations from their functions on the Board of Directors, subject to and with effect from the Settlement, and the Board of Directors invites you to the EGM to resolve on the agenda items and proposals 1-3 included in this invitation.

We would like to thank our shareholders for their continued trust and support and look forward to your participation at the EGM.

Legal Notice

This invitation to the EGM and the related materials and information do not constitute an offer or an offer prospectus within the meaning of article 125 *et seqq.* of the Financial Market Infrastructure Act ("**FinMIA**") (nor a summary thereof), nor a report of the Board of Directors within the meaning of article 132 para. 1 FinMIA (nor a summary thereof) and are not part of the Offer documentation in connection with the Offer. The terms and conditions of the Offer are set forth solely in the Offer documentation, which is available at www.samsungbiologics.com/offer, in particular in the Offer Prospectus, and any acceptance of the Offer should be made exclusively on the basis of such Offer documentation and the terms and conditions set forth therein.

Agenda and proposals

(English translation of the binding German original)

1. Granting discharge to the members of the Board of Directors and Executive Committee

Proposal: The Board of Directors proposes that the EGM grants discharge from liability to all members of the Board of Directors and Executive Committee in office for their activities in the financial year 2026 up to and including the date of this EGM.

Explanations: Pursuant to article 698 para. 2 item 7 of the Swiss Code of Obligations ("CO") and the Articles of Association, the General Meeting is responsible for the discharge resolution.

2. Elections

All incumbent members of the Board of Directors have tendered their resignations from their functions on the Board of Directors, subject to and with effect from the Settlement.

The Board of Directors proposes the election of the following persons as new members of the Board of Directors, as new Chair of the Board of Directors and as new members of the Remuneration and Nomination Committee, in each case subject to and with effect from the Settlement:

2.1. Election of new members of the Board of Directors

Proposal: The Board of Directors proposes that the EGM individually elects each of the following persons as a member of the Board of Directors for a term of office ending at the conclusion of the next annual General Meeting, each election being subject to and effective as of the Settlement:

2.1.1. John Chongbo Rim

2.1.2. Seungho Ryu

2.1.3. Cheol Woo Ryu

2.1.4. Mihyun Yang

2.1.5. Joonkyung Seong

Explanations: Pursuant to article 698 para. 2 item 2 and article 698 para. 3 item 1 and 2 CO, as well as the Articles of Association, the General Meeting individually elects the members of the Board of Directors, the Chair of the Board of Directors, and the members of the Remuneration and Nomination Committee (see also agenda items 2.2 and 2.3).

The individuals proposed for election were nominated by Samsung Biologics in accordance with the Transaction Agreement. For information regarding the current activities and CVs of each nominee proposed for election, please refer to the following website: www.polypeptide.com/investors/general-meeting/. The

elections and the resignations of the incumbent members of the Board of Directors (see above) are subject to and effective as of the Settlement, which ensures that the changes in the Board of Directors, its Chair, and the Remuneration and Nomination Committee will only take effect once the Offer has been settled.

The Board of Directors makes these proposals for the election of the persons nominated by Samsung Biologics for the purpose of satisfying the Offer condition set forth in Section B.7.1(g) of the Offer Prospectus (see also above).

2.2. Election of new Chair of the Board of Directors

Proposal: The Board of Directors proposes that the EGM elects John Chongbo Rim as new Chair of the Board of Directors for a term of office ending at the conclusion of the next annual General Meeting, subject to his election as a member of the Board of Directors, such election being subject to and effective as of the Settlement.

Explanations: Please refer to the explanations under agenda item 2.1.

2.3. Election of new members of the Remuneration and Nomination Committee

Proposal: The Board of Directors proposes that the EGM individually elects each of the following persons as a member of the Remuneration and Nomination Committee for a term of office ending at the conclusion of the next annual General Meeting, subject to their election as a member of the Board of Directors, such election being subject to and effective as of the Settlement:

2.3.1. Cheol Woo Ryu

2.3.2. Seungho Ryu

Explanations: Please refer to the explanations under agenda item 2.1.

3. Amendment of the Articles of Association

Proposal: The Board of Directors proposes to amend the Articles of Association as follows, subject to all of the Offer conditions set forth in the Offer Prospectus, other than the Offer condition set forth in Section B.7.1(e) of the Offer Prospectus, having been satisfied or waived:

Current Version	Proposed Amended Version (additions <u>underlined</u> / deletions crossed out)
ARTICLE 5: SHARE REGISTER, TRANSFER RESTRICTIONS	ARTICLE 5: SHARE REGISTER, TRANSFER RESTRICTIONS
² Except as otherwise provided in these Articles of Association, persons acquiring registered shares shall on application be entered in the share register without limitation as shareholders with voting rights, provided they expressly declare themselves (i) to have acquired the said shares in their own name and for their own account, (ii) that no agreements on the redemption or return of these registered shares exist, (iii) to bear the risk associated with the shares and (iv) comply with the disclosure requirements stipulated by the Federal Act on Financial Market Infrastructures and Market Conduct in Securities and Derivatives Trading of 19 June 2015 (“FinMIA”). Entry in the share register of registered shares as a shareholder with voting rights is subject to the approval of the Company. Entry in the share register of registered shares as a shareholder with voting rights may be refused based on the grounds set out in Article 5 paras. 3-7. If the Company does not refuse to register the acquirer as shareholder with voting rights within 20 calendar days upon receipt of the application, the acquirer is deemed to be a shareholder with voting rights. Non-recognized acquirers shall be entered in the share register as shareholders without voting rights. The corresponding shares shall be considered as not represented in the General Meeting of Shareholders.	² Except as otherwise provided in these Articles of Association, persons acquiring registered shares shall on application be entered in the share register without limitation as shareholders with voting rights, provided they expressly declare themselves (i) to have acquired the said shares in their own name and for their own account, (ii) that no agreements on the redemption or return of these registered shares exist, (iii) to bear the risk associated with the shares and (iv) comply with the disclosure requirements stipulated by the Federal Act on Financial Market Infrastructures and Market Conduct in Securities and Derivatives Trading of 19 June 2015 (“FinMIA”). Entry in the share register of registered shares as a shareholder with voting rights is subject to the approval of the Company. Entry in the share register of registered shares as a shareholder with voting rights may be refused <u>if the prerequisites based on the grounds</u> set out in <u>this Article 5 paras. 3-7 are not met</u>. If the Company does not refuse to register the acquirer as shareholder with voting rights within 20 calendar days upon receipt of the application, the acquirer is deemed to be a shareholder with voting rights. Non-recognized acquirers shall be entered in the share register as shareholders without voting rights. The corresponding shares shall be considered as not represented in the General Meeting of Shareholders.
³ The Board of Directors may refuse the registration in the share register as a shareholder with voting rights if an acquirer would as a result of the recognition as a shareholder with voting rights directly or indirectly acquire, or hold in the aggregate, more than 10 percent of the registered shares recorded in the commercial register (the “Percentage Limit”).	³ [canceled] The Board of Directors may refuse the registration in the share register as a shareholder with voting rights if an acquirer would as a result of the recognition as a shareholder with voting rights directly or indirectly acquire, or hold in the aggregate, more than 10 percent of the registered shares recorded in the commercial register (the “Percentage Limit”).
⁴ The Board of Directors may enter the registration with voting rights in the share register, even if 10 percent of the registered shares recorded in the commercial register are exceeded,	⁴ [canceled] The Board of Directors may enter the registration with voting rights in the share register, even if 10 percent of the registered shares recorded in the commercial register are exceeded,

Current Version	Proposed Amended Version (additions <u>underlined</u> / deletions crossed out)
(a) for shareholders (and their respective legal successors) who held or were allotted more than 10 percent of the registered shares recorded in the commercial register before completion of the initial public offering of the Company ("IPO") and only to the extent they held or were allotted such registered shares at that time ("Incumbent Shareholders"); (b) if an Incumbent Shareholder (or such Incumbent Shareholder's legal successor, respectively) acquires additional registered shares after the IPO; or (c) if (i) a spouse, descendent, parent, sibling or an affiliated person of an Incumbent Shareholder (or such Incumbent Shareholder's legal successor, respectively) or (ii) any other acquirer acquires registered shares from an Incumbent Shareholder (or such Incumbent Shareholder's legal successor, respectively) off-market, but in each case only to the extent such registered shares held by such Incumbent Shareholder (or such Incumbent Shareholder's legal successor, respectively) had been registered with voting rights in the share register.	(a) for shareholders (and their respective legal successors) who held or were allotted more than 10 percent of the registered shares recorded in the commercial register before completion of the initial public offering of the Company ("IPO") and only to the extent they held or were allotted such registered shares at that time ("Incumbent Shareholders"); (b) if an Incumbent Shareholder (or such Incumbent Shareholder's legal successor, respectively) acquires additional registered shares after the IPO; or (c) if (i) a spouse, descendent, parent, sibling or an affiliated person of an Incumbent Shareholder (or such Incumbent Shareholder's legal successor, respectively) or (ii) any other acquirer acquires registered shares from an Incumbent Shareholder (or such Incumbent Shareholder's legal successor, respectively) off-market, but in each case only to the extent such registered shares held by such Incumbent Shareholder (or such Incumbent Shareholder's legal successor, respectively) had been registered with voting rights in the share register.
⁸ The Company may in special cases approve exceptions to the above restrictions (Article 5 para. 3, 4 and 5). After due consultation with the persons concerned, the Company is further authorized to delete entries in the share register as shareholder with voting rights with retroactive effect if they were effected on the basis of false information or if the respective person does not provide the information pursuant to Article 5 para. 3. The concerned person has to be immediately informed about the deletion.	⁸ The Company may in special cases approve exceptions to the above restrictions (Article 5 para. 3, 4 and 5) <u>prerequisites</u>. After due consultation with the persons concerned, the Company is further authorized to delete entries in the share register as shareholder with voting rights with retroactive effect if they were effected on the basis of false information or if the respective person does not provide the information pursuant to Article 5 para. 3. The concerned person has to be immediately informed about the deletion.
ARTICLE 11: VOTING RIGHTS, REPRESENTATION, RESOLUTIONS	ARTICLE 11: VOTING RIGHTS, REPRESENTATION, RESOLUTIONS
³ No shareholder or proxy may, directly or indirectly, exercise voting rights attached to own or represented shares that would collectively exceed 10 percent of the registered shares recorded in the commercial register.	³ [canceled] No shareholder or proxy may, directly or indirectly, exercise voting rights attached to own or represented shares that would collectively exceed 10 percent of the

Current Version	Proposed Amended Version (additions <u>underlined</u> / deletions crossed out)
	registered shares recorded in the commercial register.
⁴ Legal entities or partnerships or other associations or joint ownership arrangements which are linked through capital ownership or voting rights, through common management or in like manner, as well as individuals, legal entities or partnerships (especially syndicates) which act in concert are considered as one shareholder for the purposes of such voting.	⁴ <u>[canceled]</u> Legal entities or partnerships or other associations or joint ownership arrangements which are linked through capital ownership or voting rights, through common management or in like manner, as well as individuals, legal entities or partnerships (especially syndicates) which act in concert are considered as one shareholder for the purposes of such voting.
⁵ The restriction of voting rights pursuant to paragraphs 3 and 4 of this article 11 shall not apply to the exercise of voting rights by shareholders or their proxies (including the Independent Proxy), to the extent that their shares are registered with voting rights in the share register in accordance with article 5 para. 4.	⁵ <u>[canceled]</u> The restriction of voting rights pursuant to paragraphs 3 and 4 of this article 11 shall not apply to the exercise of voting rights by shareholders or their proxies (including the Independent Proxy), to the extent that their shares are registered with voting rights in the share register in accordance with article 5 para.4.

Explanations: Pursuant to article 698 para. 2 item 1 CO and the Articles of Association, the General Meeting is responsible for the amendment of the Articles of Association.

The proposed amendments relate to the removal from the Articles of Association of the transfer restrictions (*Vinkulierung*) pursuant to Article 5 para. 3 of the Articles of Association and the voting limitations (*Stimmrechtsbeschränkungen*) pursuant to Article 11 para. 3 of the Articles of Association and include certain consequential changes in other paragraphs of these Articles.

The complete Articles of Association, including the proposed amendments, are available on the following website: www.polypeptide.com/investors/general-meeting/.

The resolution of the EGM to amend the Articles of Association is subject to the satisfaction or waiver of all of the Offer conditions set forth in the Offer Prospectus, other than the Offer condition set forth in Section B.7.1(e) of the Offer Prospectus. The Board of Directors will apply for registration of the amendments to the Articles of Association in the Commercial Register when all such Offer conditions have been satisfied or waived.

The Board of Directors makes this proposal to amend the Articles of Association for the purpose of satisfying the Offer condition set forth in Section B.7.1(e) of the Offer Prospectus (see also above).

Organizational notes

Date: 26 October 2026, 18.00 CET (doors open at 17.30 CET)
Form: In-person EGM at Dialoghotel Eckstein, Langgasse 9, 6340 Baar, Switzerland

1 Record Date for the share register, access and voting cards

Only shareholders entered in the share register with voting rights on 16 October 2026, at 17.00 (CEST), are entitled to exercise their voting rights at the EGM. This also applies to shareholders who have tendered their shares into the Offer.

Since the booking to the second trading line of shares that have been tendered into the Offer may result in a deregistration from the share register, shareholders who tender their shares into the Offer and who wish to exercise their voting rights at the EGM are urged to verify that their tendered shares are (re-)registered with voting rights in the share register and to give the necessary instructions to their custodian bank to request their (re-)registration in due time before the above-mentioned record date for the EGM.

From 16 October 2026, 17.01 (CEST), to and including 26 October 2026, no new entries will be made in the share register that would create a right to vote at the EGM.

Shareholders that are registered with voting rights in the share register on the above-mentioned record date and who tender their shares into the Offer after the record date will only be entitled to vote at the EGM if the tendered shares are (re-)registered with voting rights in the share register prior to the EGM and registered with voting rights in the share register at the time of the EGM. Shareholders who tender their shares into the Offer after the record date and who wish to exercise their voting rights at the EGM are therefore urged to verify that their tendered shares are (re-)registered with voting rights in the share register and to give the necessary instructions to their custodian bank to request their (re-)registration in due time before the EGM.

Shareholders who sell part or all their shares prior to the EGM are no longer entitled to vote with respect to the shares sold.

Shareholders who wish to attend the EGM personally should return the enclosed reply form in the provided envelope by 20 October 2026 at the latest to: PolyPeptide Group AG, c/o areg.ch AG, Fabrikstrasse 10, 4614 Hägendorf, Switzerland. Upon due return of the completed reply form, the admission and voting cards will be sent by mail. Shareholders can find further guidance in the enclosed reply form.

Information about the voting results at the EGM will be published following the EGM and will be available at www.polypeptide.com/investors/general-meeting/.

2 Exercise of voting rights and representation

Shareholders may be represented at the EGM by the Independent Proxy or a third

party that shareholders are free to designate by means of a written proxy.

The annual General Meeting held in 2026 re-elected ADROIT Attorneys, Kalchbühlstrasse 4, 8038 Zurich, Switzerland, represented by Mr. Roger Föhn, as Independent Proxy. The enclosed reply form serves exclusively to grant power of attorney to the Independent Proxy. Shareholders wishing to be represented by the Independent Proxy are kindly requested to fill in the reply form and return it by mail using the enclosed envelope. Forms must be received by 23 October 2026. Please allow appropriate time for delivery. Shareholders that have instructed the Independent Proxy or a third party to represent them are not allowed to participate in the EGM.

3 Remote electronic voting, electronic order of admission and voting cards

Shareholders may optionally also issue electronic authorizations and instructions to the Independent Proxy and submit orders for admission cards at polypeptide.netvote.ch. The requisite login data is enclosed in the invitation supplied to shareholders. Shareholders may change any instructions they may have communicated electronically up to, but no later than, 23.59 (CEST) on 22 October 2026. Shareholders who exercise their voting rights online are asked not to additionally return their registration form by mail.

4 Language

The EGM will be held in German.

5 Speakers' desk

Shareholders who wish to speak are kindly asked to notify the speakers' desk (*Wortmeldeschalter*) at the venue before the EGM begins.

6 Transport

We recommend that shareholders make the journey by public transport (www.sbb.ch/en).

7 Questions

If shareholders have any questions about the EGM, please contact PolyPeptide Investor Relations (investorrelations@polypeptide.com / +41 43 502 05 80) or the share register areg.ch ag (info@areg.ch / +41 62 209 16 60). If shareholders would like to report a change of address, please contact the share register areg.ch ag (info@areg.ch). Please note that changes of address should also be reported to the bank.

8 Attachments

- Registration form (with form for proxy and instructions to the Independent Proxy)
- Reply envelope

